Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs around €58,500 in 2024. Unfortunately 99,8 % of our readers do not donate. If everyone reading this appeal made a small contribution, our fundraising campaign for 2024 would be over after a few days. This appeal is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute to support ADxS.org with your donation. Thank you very much!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V. Donations to ADxS e.V. are tax-deductible in Germany (up to €300, the remittance slip is sufficient as a donation receipt).

If you would prefer to make an active contribution, you can find ideas for Participation or active support here.

$45213 of $63500 - as of 2024-10-31
71%
ADxS.org Logo
ADxS.org Logo
Search Donations Addresses Recent changes ADHS-Forum Deutsche Version
Register

Already have an account? Login

Header Image
Frequency of ADHD (prevalence)

Sitemap

The ADxS.org project
Abstract from ADxS.org
Symptoms
Consequences of ADHD
Origin
Stress
Neurological aspects
Diagnostics
Prevention
Treatment: Guide and Effect size
Treatment: Medication for ADHD
Non-drug treatment
Addresses
This and that about ADHD
Tests and surveys
Forum

Frequency of ADHD (prevalence)

Previous page Next page

ADHD exists in all cultures and countries worldwide. The frequency of occurrence is called prevalence.

Prevalence can define different terms:
Diagnosis prevalence: Frequency of existing medical diagnoses of a disease in the total population (e.g. within the last 12 months). Dependent on the diagnostic scale and expertise of the person making the diagnosis.
True prevalence / field prevalence / epidemiological prevalence: Frequency of a disease in a thorough examination of a representative group by experts, extrapolated to the total population. This value also depends on the instruments used (for ADHD, for example, higher in DSM 5 than in DSM III).
Treatment prevalence: Prevalence determined on the basis of treatment/prevention contacts. Dependent on the commitment to treatment of people with ADHD.
Administrative prevalence: Prevalence determined from routine statistics (e.g. cancer register). Barely possible for ADHD.

Point prevalence: Number of existing cases at a point in time.
Period prevalence: All cases occurring in a period.

Incidence: Frequency of new diagnoses of a disease in the overall population (e.g. within the last 12 months).

The diagnostic prevalence of ADHD, i.e. the frequency with which practicing doctors and psychologists diagnose ADHD, has risen sharply in recent years as ADHD has become better understood and doctors and psychologists are now better trained. However, the true prevalence, i.e. the frequency with which ADHD actually exists, has not changed. In test studies in which representative groups are examined by specialists, the true prevalence of ADHD remains unchanged.1

If we use the term prevalence without further explanation, this should in future refer to diagnosis prevalence. As of April 2021, this differentiation has not yet been consistently verified, which is made more difficult by the fact that a number of studies do not formulate this transparently.

1. Population prevalence

1.1. Worldwide

An overall average prevalence of 5.29% was determined in 2007 from studies conducted between 1978 and 2005.2 Few differences were found between North America and Europe, while the figures for Africa and the Middle East differed.
A meta-analysis determined an ADHD prevalence in adults of 3.10 %.3 ADHD-I was more common than ADHD-HI, ADHD-C was the least common.

Children and young people:
A comprehensive study of 13 meta-analyses (588 primary studies with 3,277,590 subjects) determined a worldwide ADHD prevalence in children and adolescents of 8% (boys: 10%, girls: 5%). The most common ADHD subtype was ADHD-I, followed by ADHD-HI and ADHD-C.4
in 2018, a study found a prevalence of around 5% in children and adolescents and a further 5% just below the cut-off for a diagnosis.5 in 2015, a meta-analysis of 175 studies according to DSM III to DSM IV found a worldwide pooled overall prevalence of ADHD in children and adolescents of 7.2% (6.7% to 7.8%).6 in 2012, a meta-analysis of 86 studies with n = 163,688 children and adolescents determined a prevalence of 5.9 % to 7.1 % according to DSM IV7

Adults
in 2012, a meta-analysis of 11 studies with n = 14,112 adults determined a prevalence of around 5% according to DSM IV7

A study conducted worldwide using the same standardized methods on adults aged 18 to 44 years according to the DSM-IV criteria (aimed at children) found an ADHD prevalence of 2.8% and was higher in high (3.6%) and upper middle (3.0%) income countries than in low/lower middle income countries (1.4%).8 We are critical of the design of the study because a pre-selection of subjects was made in a preliminary study. We consider it questionable that adult ADHD should be more common than ADHD in children above the treshold, especially since DSM IV was used as a diagnostic tool tailored to ADHD in children and adolescents.

Country Prevalence in children (Treshold) Prevalence in children (Subtreshold) Prevalence in adults
Belgium 2.9 % 8.6 % 4.1 %
France 4.7 % 8.9 % 7.3 %
Germany 1.8 % 5.6 % 3.1 %
Italy 0.9 % 3.7 % 2.8 %
Netherlands 2.9 % 9.2 % 5.0 %
Northern Ireland 3.2 % 4.5 % 6.0 %
Poland 0.3 % 0.8 % 0.8 %
Portugal 1.5 % 4.0 % 3.0 %
Spain 1.8 % 1.9 % 1.2 %
Spain (Murcia) 2.0 % 4.2 % 3.3 %
USA 8.1 % 6.6 % 5.2 %
Brazil (Sao Paulo) 2.5 % 7.0 % 5.9 %
Colombia (Medellin) 2.5 % 3.0 % 3.0 %
Lebanon 1.5 % 3.3 % 1.8 %
Mexico 3.0 % 3.7 % 1.9 %
Romania 0.4 % 0.7 % 0.6 %
Colombia 1.2 % 2.9 % 2.5 %
Iraq 0.1 % 1.0 % 0.6 %
Peru 0.8 % 2.5 % 1.4 %
China (Shenzen) 0.7 % 3.0 % 1.8 %

The following differences in (diagnostic) prevalence in different regions of the world are likely to represent differences in diagnostic methodology rather than differences in the true prevalence of ADHD.9

1.2. Europe

1.2.1. Germany

The first KiGGS study in 2006 found that just under 5% of children and adolescents in Germany aged between 3 and 17 had already received a medical diagnosis of ADHD (diagnosis prevalence). In addition, a further 5% can be classified as suspected cases 10
The second KiGGS study from 2017 speaks of 4.4% of children and adolescents who have already received a medical diagnosis.1112 These are reports from parents or guardians. The statement that an ADHD diagnosis had been made once does not mean that this diagnosis still had to persist at the time of the study survey. It is not the field prevalence (“true prevalence”, study of a randomized group by experts), as the assessment is influenced by the ADHD knowledge of the medical profession. The field prevalence will therefore be higher.

The overall prevalence of ADHD in children and adolescents was found to be 2.2% in the 2007 Bella study13 (which we consider to be too low). A Bella sub-study with n= 2500 subjects between the ages of 7 and 1714 puts the prevalence in the parents’ assessment at around 5%. Both studies confirm a strong divergence in prevalence according to social class. According to the Bella Study 2007, the middle class has the average prevalence, while the lower social class has a prevalence of 3.9%, which is four times higher than the upper class.15 The Bella sub-study reports a prevalence of ADHD in the lower social class (at 7.2%) that is approximately 2.3 times as high as in the upper class at 2.8% (with 3 strata).14

In older adults, one study found an ADHD field prevalence of:16

  • 40-59-year-olds: 3.1 %
  • 60-80 year olds: 2.1 %
    With regard to current ADHD symptoms, 92.1% of the results of the self-assessment instrument used matched those of the external observation instrument.

Another study found a field prevalence (epidemiological prevalence) in adults of 4.7%.17
In Germany, 20% of psychiatric and psychotherapeutic patients are said to be affected by ADHD.18

33.3% of all Germans and 38.8% of all EU citizens suffer from a mental disorder (within 12 months). Men and women are affected in roughly equal numbers, but with different types of disorder. The age group of 18 to 34 years is most frequently affected.19
Of these 33.3%, 1/3 (i.e. a total of 11.1% of all Germans) suffer from more than one Disorder. In these cases, there is an overt comorbidity of several disorders from different diagnostic groups. The comorbidity with regard to different individual diagnoses from the same group is significantly higher again.
Comorbidities increase with age.19

The lifetime prevalence of ADHD in Germany is roughly equivalent to that of diabetes.20

Further information on the prevalence distribution of ADHD: http://www.adhs.info/fuer-paedagogen/allgemein-stoerungsbild/praevalenzraten.html

1.2.2. Denmark

A cohort study in Denmark found a prevalence of 5.9% in boys under 18 years of age according to ICD 10.21 Another study of all children born between 1990 and 199 found a prevalence of 3.68%.22

1.2.3. Finland

In Finland, a national cohort study observed an increase in the use of ADHD medication in children from 1.26% in 2008 to 4.42% in 2018 and in adolescents from 0.93% in 2008 to 4.21% in 2018. At the same time, the proportion of women on medication increased.23
received ADHD treatment with medication in 201924

  • 1.3 % of boys
  • 0.48 % of the girls

1.2.4. France

The prevalence of ADHD in children aged 6 to 12 was reported to be between 3.5% and 5.6%. Another study gives a value of 0.3%,25 which seems too low.

1.2.5. Czech Republic

In a representative cross-section of the population, the diagnostic prevalence in 2019 was 3% and the field prevalence (according to the very simple ASRS) was 7.84%.26

1.2.6. Ireland

7,6 %27

1.2.7. Iceland

For Iceland, a prescription rate for ADHD medication was reported for 2023 (according to the Icelandic state prescription register) for28
14.7 % of 7- to 17-year-olds (boys 17.7 %, girls 11.6 %)
17.6 % of 12 to 17-year-olds (boys 20.1 %, girls 14.6 %)
10.2 % of 18 to 44-year-old adults (men 9.4 %, women 11.0 %)

The prevalence of diagnosis must therefore be at least as high.

The increase in the prescription rate from 2010 to 2023 amounted to
for 7- to 17-year-olds: 93 % boys, 224 % girls
for 18- to 44-year-olds: 414 % men, 543 % women

As a hypothesis, it is conceivable that immigration countries have a higher rate of ADHD because more impulsive people are more likely to emigrate in times of need.
Iceland was a country of immigration for emigrating Scandinavians, the USA was and is a country of immigration. Both have an above-average prevalence of ADHD.
This hypothesis should be accompanied by a mirror image of reduced ADHD rates in emigration countries. At least for Ireland, this does not appear to be the case.

1.3. North America

1.3.1. USA

In the US, the incidence of diagnosis of all developmental disorders, including ADHD, has increased significantly from 2009 to 2018:293031

By age:

  • Adults: 14.6 % (DSM 5)32
  • Children
    • Children aged 3 to 17 with a diagnosis of ADHD (diagnosis prevalence)
      • 2010: 8 %
      • 2017: 8.5 % to 9.5 %29
      • 2018: 9,8 %
      • 2020 to 2022: 11.3 %33
      • Boys
        • 2010: 11 %
        • 2018: 13 %
        • 1997 to 2018: 12.93 %34
        • 2020 to 2022: 14.5 %33
      • Girls
        • 2010: 6 %
        • 2018: 6,6 %
        • 1997 to 2018: 5.61 %34
        • 2020 to 2022: 8.0 %33
        • Black girls aged 7 to 17: 6.4% to 9.2%; the inattentive subtype was most common35
        • White girls between 7 and 17 years: 2.3% to 6.4%; the inattentive subtype was most common35
      • By age
        • 3-4: Learning disability 3.2%, ADHD 1.2% (2018)
        • 5-9: ADHDS 6.57 % (1997-2018)34
        • 5-11: Learning disability 6.7 %, ADHD 9 % (2018)
        • 12-17: Learning disability 9.4%, ADHD 13.6% (2018)
        • 10-17: ADHD 11.09 % (1997-2018)34
    • Children aged 4 to 17 in a nationwide telephone survey (diagnosis prevalence)36
      • 2003: 7,8 %
      • 2007: 9.5 %; 4.8 % taking ADHD medication
      • 2019/2020: 8,5 %37
    • Children aged 5 to 11 in California (diagnosis prevalence)38
      • 2001: 2,1 %
      • 2010: 3,1 %

By ethnicity:

  • Hispanic children (2010: 4 %; 2018: 6.9 %)39

  • non-Hispanic white children (2010: 10 %; 2018: 10.9 %)39

  • non-Hispanic black children (2010: 11 %; 2018: 13.1 %) Children39

  • Children of couples with one white and one Native American parent (American Indian / Alaska Native) 2018: 26.4 %39

  • People who identify as two or more races: ADHDS 12.36% (1997-2018)34

  • Whites: ADHD 9.83% (1997-2018)34

  • Blacks/African Americans: ADHD 10.09% (1997-2018)34

  • Hispanic/Latino: ADHD 5.36% (1997-2018)34

  • Non-Hispanic/Latino: ADHD 10.64% (1997-2018)34

  • Below the poverty line: ADHD 11.41 % (1997-2018)34

  • Income from 100 to 199 % of the poverty line: ADHD 10.6 % (1997-2018)34

  • Income from 200 to 399 % of the poverty line: ADHD 8.6 % (1997-2018)34

  • Income of 400% or more of the poverty line: ADHD 8.39% (1997-2018)34

  • Medicaid recipients: ADHD 12.57% (1997-2018)34

  • Privately insured: ADHD 9.65 % (1997-2018)34

  • Insured persons: ADHD 8.11 % (1997-2018)34

  • Uninsured: ADHD 5.83 % (1997-2018)34

Children of single mothers were around twice as likely to have learning difficulties (2010: 12%; 2018: 11.3%) or ADHD (2010: 13%; 2018: 12.6%) as children in families with two parents (learning difficulties 2010: 6%, 2018: 5.9%; ADHD 2010: 7%, 2018: 8.8%). In 2018, only 5% of children of single fathers had learning difficulties and 6.7% had ADHD.
Children with average or poor health were around five times as likely to have a learning disability (2010: 28% to 6%; 2018: 32.3% to 5.9%) and around twice as likely to have ADHD (2010: 18% to 7%; 2018: 16.2% to 8.8%) as children with excellent or very good health. At 15.4%, ADHD was barely more common among children in good health in 2018 than among those in average or poor health.
Children in cities with over 1 million inhabitants were less likely to be diagnosed with ADHD in 2018 (8.2%) than children in cities with less than 1 million inhabitants (12%) or outside of large cities (11.6%).
Between 2009 and 2016, an increase in the annual prevalence of ADHD of around 250% from 0.23% to 0.84% was observed in war veterans.39
Friedmann reports that the lifetime prevalence of ADHD in the USA has risen from 7.8% in 2003 to 11% in 2011.40 This is not due to an increase in ADHD (true prevalence), but to the fact that ADHD is now better recognized and more reliably diagnosed (diagnostic prevalence).

A 20-year study from 1997 to 2016 in the USA found diagnosis prevalence in children and adolescents:41

  • 6.1 % in 1997/1998
  • 10.2 % in 2015/2016, of which
    • Boys 14.0 %
    • Girls 6.3 %
    • hispanic 6.1 %
    • non-Hispanic white 12.0 %
    • non-Hispanic black 12.8 %

The increase in diagnosis prevalence is likely explained by the improved diagnosis of ADHD. The true prevalence of ADHD in children in the USA did not change between 2003 and 2007.9

One study found very different ADHD prevalences by county. The data was collected through parental reports, which severely impairs its validity:42
USA national: 12.9 % (11.5 % to 14.4 %)
Areas with a high prevalence of ADHD:

  • West South Central: 55.1% of counties had a prevalence of 16% or more
  • East South Central: 53.6% of counties had a prevalence of 16% or more
  • New England: 49.3% of counties had a prevalence of 16% or more
  • South Atlantic: 46.2% of counties had a prevalence of 16% or more
    Areas with a low prevalence of ADHD:
  • East North Central: 11.7% of counties had a prevalence of 16% or more
  • Pacific: 6.9% of counties had a prevalence of 16% or more
  • West North Central: 5.8% of counties had a prevalence of 16% or more
  • Mid Atlantic: 4% of counties had a prevalence of 16% or more
  • Mountain: 2.1% of counties had a prevalence of 16% or more

1.3.2. Canada

Canadian children diagnosed with ADHD were43

  • Girls
    • 2008: 3,1 %
    • 2015: 3,9 %
  • Boys:
    • 2008: 8 %
    • 2015: 9,5 %

In contrast, the calculated true prevalence was44

  • 4 - 17 years
    • 2008: 6,92 %
      • Girls: 6.0 %
      • Boys: 7.9 %
    • 2015: 8,57 %
      • Girls: 6.5 %
      • Boys: 10.1 %
  • 18 - 34 years
    • 2008: 5,73 %
      • Women: 5.4 %
      • Men: 6.2 %
    • 2015: 7,33 %
      • Women: 6.3 %
      • Men: 8.6 %
  • 35 - 64 years
    • 2008: 5,20 %
      • Women: 5.2 %
      • Men: 5.3 %
    • 2015: 5,54 %
      • Women: 5.4 %
      • Men: 5.7 %

1.4. South America

1.4.1. Colombia

One study found an ADHD prevalence of 16.4% among Paisa children in Colombia (boys 19.8%, girls 12.3%).45

1.5. Asia

East Asian (N = 1301) and South Asian (N = 730) adolescents were significantly less likely to have an ADHD diagnosis than White adolescents:46

  • East Asian adolescents: OR = 0.16
  • South Asian adolescents: OR = 0.45

1.5.1. China

In China, a prevalence of 6.26% was found in children and adolescents (63 studies from 1983 to 2015, 70% of which were conducted between 2005 and 2015), with significant regional differences.47

1.5.2. Japan

Among Japanese adults, the prevalence of ADHD is said to be 1.7%.48

Among Japanese female students (∅ 19.2 years), ADHD-HI was found in 27.2% and ADHD-I in 1.1%.49 Another study reported 27% ADHD in Japanese students (29.7% males, 25.3% females).50

One study reported 31.1% ADHD by parent report (n = 7,566) and 4.3% ADHD by teacher report (n = 9,9 56) with an overall prevalence of 7.2 to 7.9% among Japanese preschool children. It is possible that parental reports in Japan are not reliable for cultural reasons.51 Another study also found evidence of excessive parental ratings for young children in Japan.52 While the parents of 4 to 12-year-olds identified an ADHD rate of 7.7%, the children’s teacher ratings revealed ADHD in only 3.19% (according to DSM III).

1.5.3. Taiwan

A large study found an increase in new ICD 9 ADHD diagnoses from 7.92/10000 person-years in 2000 to 13.92/10000 person-years in 2011, with the male to female ratio decreasing from 3.61 to 2.90. The largest increase was found in young adults (19-30 years), followed by preschoolers (0-6 years).53

1.5.4. India

A large study put the prevalence of ADHD in India in 2017 at 0.3%.54 The prevalence of ASD was put at 3.2%.

In a rural area of northern India, a prevalence of AD55

1.6. Africa

A meta-analysis of 63 studies with n = 849,902 participants found a mean prevalence of 10.3% for the Middle East and North Africa.56

1.6.1. Ethiopia

In Ethiopia in 2022, a study of children and adolescents aged 6 to 17 years found a field prevalence of 13%.57 in 2015, a study of 6 to 17-year-olds found a prevalence of 7.3%. There were 80% more boys than girls affected, children of single parents were 5 times more likely to be affected and children from families with a low socio-economic status were 2.4 times more likely to be affected.58 Another study found a field prevalence of 9.9%59
A meta-analysis found an overall pooled prevalence in children and adolescents of 14.2%. Risk factors were: Male (OR: 2.19), aged 6-11 years (OR: 3.67), low family socioeconomic status (OR: 3.45), maternal complications during pregnancy (OR: 3.29) and a family history of mental illness (OR: 3.83).60

1.6.2. Ghana

A study in Ghana in 2016 found a prevalence of 1.64% among children aged 7 to 15.61

1.6.3. Somalia

A study in Somalia found a prevalence of 2.8% in children aged 7 to 15.62

1.6.4. Mozambique

An ADHD prevalence of 13.4% was found among primary school pupils in Mozambique. Using stricter standards, the prevalence was 6.7%.63

1.7. Middle East

A meta-analysis of 63 studies with n = 849,902 participants found a mean prevalence of 10.3% for the Middle East and North Africa.56 The prevalence in children and adolescents (59 studies) was 10.1 %, the prevalence in adults (4 studies) was 13.5 %.

1.7.1. Iran

A meta-analysis of 19 studies found a mean prevalence of 14.8% for Iran.56

In Iran, a study published in 2019 found a prevalence of 4% (5.2% in boys, 2.7% in girls) between the ages of 6 and 18.64

1.7.2. Saudi Arabia

A meta-analysis of 14 studies with n = 455,334 persons with ADHD found an ADHD prevalence of 12.4% in the Saudi population as a whole65
A meta-analysis of 8 studies found a mean prevalence of 13.5% for Saudi Arabia.56

A study of 2280 students from 11 colleges at King Abdulaziz University, one of the largest universities in Saudi Arabia, were personally assessed with a validated Arabic version of the Adult ADHD Self-Report Scale. Of the 2059 students (90%) who completed the questionnaire (mean age: 21.2 years), 11.9% met the criteria for adult ADHD. Only 6.5% had been diagnosed with ADHD in childhood and only 0.8% had taken medication for it.
This is one of the few studies on the true prevalence (field prevalence) of ADHD.66
The risk of ADHD correlated with

  • high family income
  • poor grades in the last semester
  • Divorce of the parents
  • ADHD diagnosis in childhood
  • previous diagnosis of depression
  • higher severity of current depression and anxiety
  • Smoking cigarettes.

A study of 200 randomly selected medical students found an ADHD prevalence of 33.3% using the ASRS. Women, third-year students and the 21- to 26-year-old age group were the high-risk groups for ADHD.67 However, the ASRS is a screening instrument and therefore not very suitable for measuring prevalence.

A study of adults aged 21 to 30 (77 women) reported ADHD symptoms in 48%68
A study of young adults reported an ADHD prevalence of 34.7% using the ASRS.69

The increased prevalence of ADHD in the Arab region could be related to the high rate of marriages between blood relatives on the Arabian Peninsula (Saudi Arabia: 52%).70

1.7.3. Egypt

A meta-analysis of 9 studies found a mean prevalence of 13.3% for Egypt.56

The prevalence of ADHD in preschool children (3 to 6 years) was 10.5%. ADHD-I was the most common (5.3 %), followed by the hyperactivity form (3.4 %).71
The risk of ADHD correlated with

  • positive family history of psychological and neurological symptoms (17.9% positive vs. 9.7% negative)
  • Family history of ADHD symptoms (24.5% positive vs. 9.4% negative)
  • active smoking of the mother (21.1 % positive vs. 5.3 % negative)
  • Delivery by caesarean section (66.4 % positive vs. 53.9 % negative)
  • increased blood pressure during pregnancy (19.1 % positive vs. 12.4 % negative)
  • Drug use during pregnancy (43.6% positive vs. 31.7% negative)
    Significant risk factors for children were:
  • Lead exposure (25.5% positive compared to 12.3% negative)
  • Children with heart problems (38.2% positive compared to 16.6% negative)
  • Hours a child spent in front of the TV or cell phone (any screen) per day (60.0% of children who tested positive spent more than 2 hours per day compared to 45.7% negative).

The prevalence of ADHD in medical students was 11.0%.72

1.7.4. Jordan

A meta-analysis of 2 studies found a mean prevalence of 23.4% for Jordan (one study with 40.6%, one study 6.2%).56

2. ADHD prevalence differences by ethnicity

The prevalence of ADHD apparently differs between different ethnic groups.
As ADHD is largely genetic, a different prevalence between different ethnic groups would not be surprising. In our opinion, these differences cannot be explained solely by differences in cultural tolerance for externalizing symptoms and the frequency of health insurance.

Notes on the terms population and race:73

  • The term race characterizes humanity as a whole. There are no different human races.
  • The English term race does not refer to a genetic definition, but to a social construct.
  • The genetic differences between continents are gradual. For example, there are groups of people in Africa (e.g. the San) who have lighter skin than groups of people in Europe (e.g. in Andalusia). The light skin color of Europeans only developed a few thousand years ago. Before that, all people were more or less “black”.
  • Over a family tree of 4000 years, every human being is related to every other human being by blood.

2.1. ADHD prevalence differences by ethnicity in children and adolescents

  • Whites: 16.8 % (meta-analysis, n = 835,505 subjects, k = 25 studies)74
  • Blacks: 15.9 % (meta-analysis, n = 218,445, k = 26 )74
  • Asians: 12.4 % (meta-analysis, n = 66,413, k = 7)74
  • Latin Americans: 10.1 % (meta-analysis, n = 493,417, k = 24)74

A cohort study of Scottish schoolchildren examined the relative prevalence distribution by ethnicity. 100 % would be an even distribution. Asians and blacks therefore had significantly less ADHD than would have been expected based on the proportion of subjects75

  • Whites: 102.8 %
  • Other: 100 %
  • Mixed: 55.6 %
  • Colored: 33.3 %
  • Asians: 8.3 %

An American cohort study (n = 17,100) found76

  • Whiteness 100 % (comparative value)
  • African-Americans: 69 %
  • Hispanic: 50 %
  • Other ethnicities: 46 %

Children without health insurance were diagnosed less frequently. Whites were more likely to receive prescription medication for a diagnosed ADHD.

An American multicenter study (n = 4,297) found:77

  • Whiteness 100 % (comparative value)
  • African-Americans: 40 % - 42 %
  • Hispanic: 37 %

The frequency of medication use in the case of an ADHD diagnosis was slightly lower in white children.

2.2. ADHD prevalence differences by ethnicity in adults

Frequency of diagnoses given within a year to patients who use a specific medical record system78. This is not the lifetime prevalence. Study, n = 5.2 million:79

  • Whites: 0.67 - 1.42 %
  • Indigenous people: 0.56 %-1.14 %
  • Hispanic or Latino: 0.25 %-0.65 %
  • Colored: 0.22 %-0.69 %
  • Asian-American persons: 0.11 %-0.35 %
  • Pacific Islanders: 0.11 %-0.39 %
  • Individuals of other ethnicities: 0.29 %-0.71 %

3. Prevalence according to life circumstances

3.1. Prison inmates (11 % to 25 %)

Field prevalence is determined by examinations of a representative group of test persons by specialists and is to be distinguished from treatment prevalence (diagnosis prevalence), which measures the frequency of existing diagnoses on the part of the normal medical profession and therefore also measures their level of knowledge.

  • 54.4 % lifetime prevalence of ADHD in Spanish prison inmates80 with an acute prevalence of 16.4 %. The lifetime prevalence of an Axis 1 Disorder was 81.4 %.
  • 25% ADHD field prevalence (“true prevalence”) among adult prison inmates in the UK81
  • 22.2 % ADHD field prevalence in adult prisons (meta-analysis, k = 28, n = 7,710)82
  • 17% ADHD field prevalence in Canada (determined with stricter diagnostic criteria)83
  • 16.4% acute ADHD prevalence among Spanish prison inmates80
  • 11 % ADHD field prevalence in France (determined with stricter diagnostic criteria)83
  • 8.3 % ADHD field prevalence in adult prisons (meta-analysis, k = 11, n = 3,919)84; was criticized by another meta-analysis that determined a prevalence of 22.2 % by extending the data used.82

3.2. Refugees and asylum seekers under the age of 18

Among refugees and asylum seekers under the age of 18, ADHD prevalence was found to be 8.6% (1 to 16%), while PTSD (22.71%), anxiety disorders (15.77%), depression (13.81%) and ODD (1.77%) were also found (meta-analysis, k = 8, n = 779).85 In our opinion, the high levels of PTSD, anxiety disorders and depression may have masked the actual prevalence of ADHD in the target group studied.

4. Prevalence among psychiatric patients

4.1. Prevalence in outpatient psychiatric populations (17.4% to 23.9%)

Prevalence rates of were found among people undergoing outpatient psychiatric treatment

  • 14.7 to 26.1 % in adult patients of outpatient treatment centers (meta-analysis, k = 14, n = 9,444)86
  • 23.9% in France (using the ASRS, which tends to overestimate prevalence as a screening tool)87
  • 22% in the UK (ASRS and WURS).88
  • 21 % in Sweden (WURS)89
  • 17.4 % in Europe (DIVA, DSM 5 criteria)90

4.2. Prevalence in psychiatric clinics (inpatient) (59 %)

In adult inpatients at a German psychiatric clinic, 59% were diagnosed with ADHD (12-month prevalence).91

  1. Polanczyk, Willcutt, Salum, Kieling, Rohde (2014): ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014 Apr;43(2):434-42. doi: 10.1093/ije/dyt261. PMID: 24464188; PMCID: PMC4817588. ↥

  2. Polanczyk, de Lima, Horta, Biederman, Rohde (2007): The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007 Jun;164(6):942-8. doi: 10.1176/ajp.2007.164.6.942. PMID: 17541055. REVIEW, Metaanalyse von 102 Studien mit n = 171.756 ↥

  3. Ayano G, Tsegay L, Gizachew Y, Necho M, Yohannes K, Abraha M, Demelash S, Anbesaw T, Alati R (2023): Prevalence of attention deficit hyperactivity disorder in adults: Umbrella review of evidence generated across the globe. Psychiatry Res. 2023 Sep 9;328:115449. doi: 10.1016/j.psychres.2023.115449. PMID: 37708807. METASTUDY, n = 21.142.129 ↥

  4. Ayano G, Demelash S, Gizachew Y, Tsegay L, Alati R (2023): The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses. J Affect Disord. 2023 Jul 24;339:860-866. doi: 10.1016/j.jad.2023.07.071. PMID: 37495084. ↥

  5. Sayal, Prasad, Daley, Ford, Coghill (2018): ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry. 2018 Feb;5(2):175-186. doi: 10.1016/S2215-0366(17)30167-0. Epub 2017 Oct 9. PMID: 29033005. ↥

  6. Thomas R, Sanders S, Doust J, Beller E, Glasziou P (2015): Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015 Apr;135(4):e994-1001. doi: 10.1542/peds.2014-3482. PMID: 25733754. METASTUDIE ↥

  7. Willcutt (2012): The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012 Jul;9(3):490-9. doi: 10.1007/s13311-012-0135-8. PMID: 22976615; PMCID: PMC3441936. ↥ ↥

  8. Fayyad J, Sampson NA, Hwang I, Adamowski T, Aguilar-Gaxiola S, Al-Hamzawi A, Andrade LH, Borges G, de Girolamo G, Florescu S, Gureje O, Haro JM, Hu C, Karam EG, Lee S, Navarro-Mateu F, O’Neill S, Pennell BE, Piazza M, Posada-Villa J, Ten Have M, Torres Y, Xavier M, Zaslavsky AM, Kessler RC (2017): WHO World Mental Health Survey Collaborators. The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys. Atten Defic Hyperact Disord. 2017 Mar;9(1):47-65. doi: 10.1007/s12402-016-0208-3. PMID: 27866355; PMCID: PMC5325787. ↥

  9. Polanczyk, Willcutt, Salum, Kieling, Rohde (2014): ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014 Apr;43(2):434-42. doi: 10.1093/ije/dyt261. PMID: 24464188; PMCID: PMC4817588. REVIEW ↥ ↥

  10. KiGGS Studie 2006, n = 14.836 ↥

  11. KiGGS Studie 2017 ↥

  12. Schlack, Hölling, Kurth, Huss (2007): Die Prävalenz der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) bei Kindern und Jugendlichen in Deutschland. Erste Ergebnisse aus dem Kinder- und Jugendgesundheitssurvey (KiGGS) [The prevalence of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany. Initial results from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 May-Jun;50(5-6):827-35. German. doi: 10.1007/s00103-007-0246-2. PMID: 17514469. ↥

  13. Ravens-Sieberer, Wille, Bettge, Erhart (2007): Ergebnisse aus der BELLA-Studie im Kinder und Jugendgesundheitssurvey (KiGGS); Robert Koch-Institut, Berlin, BRD, Psychische Gesundheit von Kindern und Jugendlichen in Deutschland; Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2007 · 50:871–878; DOI 10.1007/s00103-007-0250-6 ↥

  14. Steinhausen, Rothenberger, Döpfner (Herausgeber) (2010): Handbuch ADHS; Grundlagen, Klinik, Therapie und Verlauf der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, Kohlhammer, Seite 136 ↥ ↥

  15. Ravens-Sieberer, Wille, Bettge, Erhart (2007): Ergebnisse aus der BELLA-Studie im Kinder und Jugendgesundheitssurvey (KiGGS); Robert Koch-Institut, Berlin, BRD, Psychische Gesundheit von Kindern und Jugendlichen in Deutschland; Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2007 · 50:871–878; DOI 10.1007/s00103-007-0250-6, Seite 875 ↥

  16. Müller M, Turner D, Barra S, Rösler M, Retz W (2023): ADHD and associated psychopathology in older adults in a German community sample. J Neural Transm (Vienna). 2023 Jan 8. doi: 10.1007/s00702-022-02584-4. PMID: 36617378. n = 539 ↥

  17. de Zwaan M, Gruss B, Müller A, Graap H, Martin A, Glaesmer H, Hilbert A, Philipsen A (2012): The estimated prevalence and correlates of adult ADHD in a German community sample. Eur Arch Psychiatry Clin Neurosci. 2012 Feb;262(1):79-86. doi: 10.1007/s00406-011-0211-9. PMID: 21499942. n = 1.655 ↥

  18. Neuy-Lobkowicz, ADHS und Depression. Abgerufen 13.02.23 ↥

  19. Jacobi, Höfler, Strehle, Mack, Gerschler, Scholl, Busch, Maske, Hapke, Gaebel, Maier, Wagner, Zielasek, Wittchen (2014): Psychische Störungen in der Allgemeinbevölkerung. Studie zur Gesundheit Erwachsener in Deutschland und ihr Zusatzmodul Psychische Gesundheit (DEGS1-MH). ↥ ↥

  20. Heidemann, Du, Scheidt-Nave (2012): Wie hoch ist die Zahl der Erwachsenen mit Diabetes in Deutschland? Robert Koch Institut ↥

  21. Dalsgaard, Thorsteinsson, Trabjerg, Schullehner, Plana-Ripoll, Brikell, Wimberley, Thygesen, Madsen, Timmerman, Schendel, McGrath, Mortensen, Pedersen (2019): Incidence Rates and Cumulative Incidences of the Full Spectrum of Diagnosed Mental Disorders in Childhood and Adolescence. JAMA Psychiatry. 2019 Nov 20. doi: 10.1001/jamapsychiatry.2019.3523. n= 99.926 ↥

  22. Keilow, Wu, Obel (2020): Cumulative social disadvantage and risk of attention deficit hyperactivity disorder: Results from a nationwide cohort study. SSM Popul Health. 2020 Jan 31;10:100548. doi: 10.1016/j.ssmph.2020.100548. PMID: 32072007; PMCID: PMC7016018. n = 632.725 ↥

  23. Vuori, Koski-Pirilä, Martikainen, Saastamoinen (2020) Gender- and age-stratified analyses of ADHD medication use in children and adolescents in Finland using population-based longitudinal data, 2008-2018. Scand J Public Health. 2020 Jan 27;1403494820901426. doi: 10.1177/1403494820901426. PMID: 31985349. ↥

  24. Kolari TA, Vuori M, RÄttÖ H, Varimo EA, Aronen ET, Saastamoinen LK, Ruokoniemi PT (2019): Incidence of ADHD medication use among Finnish children and adolescents in 2008-2019: a need for practice changes? Scand J Public Health. 2024 Feb 29:14034948231219826. doi: 10.1177/14034948231219826. PMID: 38425045. ↥

  25. Ponnou, Haliday (2020): ADHD Diagnosis and Drug Use Estimates in France: A Case for Using Health Care Insurance Data. J Atten Disord. 2020 Feb 17:1087054720905664. doi: 10.1177/1087054720905664. PMID: 32065015. ↥

  26. Vňuková M, Ptáček R, Děchtěrenko F, Weissenberger S, Ptáčková H, Braaten E, Raboch J, Anders M, Klicperová-Baker M, Goetz M (2023): Prevalence of ADHD Symptomatology in Adult Population in the Czech Republic: A National Study. J Atten Disord. 2023 Feb;27(4):447-454. doi: 10.1177/10870547221147547. PMID: 36691347. n = 1.518 ↥

  27. Lynch S, McDonnell T, Leahy D, Gavin B, McNicholas F. Prevalence of mental health disorders in children and adolescents in the Republic of Ireland: a systematic review. Ir J Psychol Med. 2023 Mar;40(1):51-62. doi: 10.1017/ipm.2022.46. PMID: 36285647. METASTUDY ↥

  28. Ingimarsson O, Gudbrandsdottir RK, Lauth BAM, Sigurdsson E (2024): [High prevalence of treatment with ADHD medicines indicates overdiagnosis of ADHD in Iceland]. Laeknabladid. 2024 Sep;110(9):402-410. Icelandic. doi: 10.17992/lbl.2024.09.804. PMID: 39221778. ↥

  29. Zablotsky, Black, Maenner, Schieve, Danielson, Bitsko, Blumberg, Kogan, Boyle (2019): Prevalence and Trends of Developmental Disabilities among Children in the United States: 2009-2017. Pediatrics. 2019 Sep 26. pii: e20190811. doi: 10.1542/peds.2019-0811. ↥ ↥

  30. Summary health statistics for U.S. children; National Health Interview Survey, 2010. Series: Vital and health statistics. Series 10, Data from the National Health Survey; no. 250; DHHS publication; no. (PHS) 2012-1578 ↥

  31. Summary health statistics for U.S. children; National Health Interview Survey, 2018. ↥

  32. Olagunju AE, Ghoddusi F (2024): Attention-Deficit/Hyperactivity Disorder in Adults. Am Fam Physician. 2024 Aug;110(2):157-166. PMID: 39172673. REVIEW ↥

  33. Wang F, Yang H, Li F, Zheng Y, Xu H, Wang R, Li Y, Cui Y (2024): Prevalence and comorbidity of anxiety disorder in school-attending children and adolescents aged 6-16 years in China. BMJ Paediatr Open. 2024 Mar 27;8(1):e001967. doi: 10.1136/bmjpo-2023-001967. PMID: 38538104; PMCID: PMC10982779. ↥ ↥ ↥

  34. Habdank-Kolaczkowski JS, Akahara PC, Ishola F, Salawu MA, Augustine SW, Ezeamii VC, David AB, Okobi E, Okobi OE (2023): Attention-Deficit Hyperactivity Disorder Among American Youth: A Comprehensive 20-Year Analysis of National Center for Health Statistics (NCHS) Data. Cureus. 2023 Nov 14;15(11):e48781. doi: 10.7759/cureus.48781. PMID: 38098925; PMCID: PMC10719878. ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥

  35. Gross IM, Gao Y, Lee MJ, Hipwell AE, Keenan K (2023): The ADHD Phenotype in Black and White Girls From Childhood to Adolescence: Results From the Community-Based Pittsburgh Girls Study. J Atten Disord. 2023 Dec 12:10870547231215281. doi: 10.1177/10870547231215281. PMID: 38084083. ↥ ↥

  36. zitiert nach Polanczyk, Willcutt, Salum, Kieling, Rohde (2014): ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014 Apr;43(2):434-42. doi: 10.1093/ije/dyt261. PMID: 24464188; PMCID: PMC4817588. REVIEW, mit n = zwischen 73.123 und 102 353 pro Jahr ↥

  37. Yang Y, Zhao S, Zhang M, Xiang M, Zhao J, Chen S, Wang H, Han L, Ran J (2022): Prevalence of neurodevelopmental disorders among US children and adolescents in 2019 and 2020. Front Psychol. 2022 Nov 24;13:997648. doi: 10.3389/fpsyg.2022.997648. PMID: 36507037; PMCID: PMC9730394. n = 14.983 ↥

  38. Getahun, Jacobsen, Fassett, Chen, Demissie, Rhoads (2013): Recent trends in childhood attention-deficit/hyperactivity disorder. JAMA Pediatr. 2013 Mar 1;167(3):282-8. doi: 10.1001/2013.jamapediatrics.401. PMID: 23338799. N = 842.830 ↥

  39. Hale, Bohnert, Spencer, Ganoczy, Pfeiffer (2020): The Prevalence and Incidence of Attention-deficit/Hyperactivity Disorder in the Veterans Health Administration From 2009 to 2016. Med Care. 2020 Mar;58(3):273-279. doi: 10.1097/MLR.0000000000001287. PMID: 32049948. n = 5,09 Millionen pro Jahr ↥ ↥ ↥ ↥ ↥

  40. Friedmann, in New York Times Online: A Natural Fix on A.D.H.D, Sunday Review, 31.10.2014 ↥

  41. Xu G, Strathearn L, Liu B, Yang B, Bao W (2018): Twenty-Year Trends in Diagnosed Attention-Deficit/Hyperactivity Disorder Among US Children and Adolescents, 1997-2016. JAMA Netw Open. 2018 Aug 3;1(4):e181471. doi: 10.1001/jamanetworkopen.2018.1471. PMID: 30646132; PMCID: PMC6324288. ↥

  42. Zgodic A, McLain AC, Eberth JM, Federico A, Bradshaw J, Flory K (2023): County-Level Prevalence Estimates of ADHD in Children in the United States. Ann Epidemiol. 2023 Jan 16:S1047-2797(23)00006-6. doi: 10.1016/j.annepidem.2023.01.006. PMID: 36657694. n = 70.000 ↥

  43. Leung, Kellett, Youngson, Hathaway, Santana (2019): Trends in psychiatric disorders prevalence and prescription patterns of children in Alberta, Canada. Soc Psychiatry Psychiatr Epidemiol. 2019 May 25. doi: 10.1007/s00127-019-01714-w. ↥

  44. Morkem, Handelman, Queenan, Birtwhistle, Barber (2020): Validation of an EMR algorithm to measure the prevalence of ADHD in the Canadian Primary Care Sentinel Surveillance Network (CPCSSN). BMC Med Inform Decis Mak. 2020 Jul 20;20(1):166. doi: 10.1186/s12911-020-01182-2. PMID: 32690025; PMCID: PMC7370518. ↥

  45. Pineda, Lopera, Palacio, Ramirez, Henao (2003): Prevalence estimations of attention-deficit/hyperactivity disorder: differential diagnoses and comorbidities in a Colombian sample. Int J Neurosci. 2003 Jan;113(1):49-71. ↥

  46. Dissanayake A, Dupuis A, Burton CL, Soreni N, Peters P, Gajaria A, Arnold PD, Schachar R, Crosbie J (2024): Racial/Ethnic Disparities in Psychiatric Traits and Diagnoses within a Community-based Sample of Children and Youth. Can J Psychiatry. 2024 Mar 1:7067437241233936. doi: 10.1177/07067437241233936. PMID: 38425291. ↥

  47. Wang, Liu, Li, Xu, Liu, Shi, Chen (2017): Prevalence of attention deficit/hyperactivity disorder among children and adolescents in China: a systematic review and meta-analysis. BMC Psychiatry. 2017 Jan 19;17(1):32. doi: 10.1186/s12888-016-1187-9. n = 275.502 ↥

  48. Nakamura, Ohnishi, Uchiyama (2013): Epidemiological survey of adult attention deficit hyperactivity disorder (ADHD) in Japan, Jpn J Psychiatr Treat, 2013. Zitiert nach Takahashi Miyatake, Kurato, Takahashi (2016): Prevalence of attention deficit hyperactivity disorder and/or autism spectrum disorder and its relation to lifestyle in female college students. Environ Health Prev Med. 2016 Nov;21(6):455-459. ↥

  49. Takahashi Miyatake, Kurato, Takahashi (2016): Prevalence of attention deficit hyperactivity disorder and/or autism spectrum disorder and its relation to lifestyle in female college students. Environ Health Prev Med. 2016 Nov;21(6):455-459. n = 375 ↥

  50. Tateno, Teo, Shirasaka, Tayama, Watabe, Kato (2016): Internet addiction and self-evaluated attention-deficit hyperactivity disorder traits among Japanese college students. Psychiatry Clin Neurosci. 2016 Dec;70(12):567-572. doi: 10.1111/pcn.12454. n = 403 ↥

  51. Soma, Nakamura, Oyama, Tsuchiya, Yamamoto (2009): Prevalence of attention-deficit/hyperactivity disorder (ADHD) symptoms in preschool children: discrepancy between parent and teacher evaluations. Environ Health Prev Med. 2009 Mar;14(2):150-4. doi: 10.1007/s12199-008-0075-4. ↥

  52. Kanbayashi, Nakata, Fujii, Kita, Wada (1994): ADHD-related behavior among non-referred children: parents’ ratings of DSM-III-R symptoms. Child Psychiatry Hum Dev. 1994 Fall;25(1):13-29. ↥

  53. Huang, Wang, Ho (2019): Trends in incidence rates of diagnosed attention-deficit/hyperactivity disorder (ADHD) over 12 years in Taiwan: A nationwide population-based study. Psychiatry Res. 2020 Jan 14;284:112792. doi: 10.1016/j.psychres.2020.112792. PMID: 31981938. n = 265.932 Patienten ↥

  54. India State-Level Disease Burden Initiative Mental Disorders Collaborators (2019): The burden of mental disorders across the states of India: the Global Burden of Disease Study 1990-2017. Lancet Psychiatry. 2019 Dec 20. pii: S2215-0366(19)30475-4. doi: 10.1016/S2215-0366(19)30475-4. ↥

  55. H)S bei Kindern von 6,3 %. Die Mehrheit (69,3 %) der AD(H)S-positiven Kinder lebte in einer Familie und gehörte der unteren / unteren Mittelschicht an. Die Studie berichtet, dass keine Fälle von AD(H)S in der Familie vorgefunden worden seien.((Sharma, Gupta, Banal, Majeed, Kumari, Langer, Akhter, Gupta, Raina (2020): Prevalence and correlates of Attention Deficit Hyperactive Disorder (ADHD) risk factors among school children in a rural area of North India. J Family Med Prim Care. 2020 Jan 28;9(1):115-118. doi: 10.4103/jfmpc.jfmpc_587_19. PMID: 32110575; PMCID: PMC7014897. n = 205 ↥

  56. Al-Wardat M, Etoom M, Almhdawi KA, Hawamdeh Z, Khader Y (2024): Prevalence of attention-deficit hyperactivity disorder in children, adolescents and adults in the Middle East and North Africa region: a systematic review and meta-analysis. BMJ Open. 2024 Jan 18;14(1):e078849. doi: 10.1136/bmjopen-2023-078849. PMID: 38238059; PMCID: PMC10806616. ↥ ↥ ↥ ↥ ↥ ↥

  57. Mulu, Mohammed, Kebede, Atinafu, Tarekegn, Teshome, Tadese, Wubetu (2022): Prevalence and Associated Factors of Attention-Deficit Hyperactivity Disorder among Children Aged 6-17 Years in North Eastern Ethiopia. Ethiop J Health Sci. 2022 Mar;32(2):321-330. doi: 10.4314/ejhs.v32i2.13. PMID: 35693560; PMCID: PMC9175227. ↥

  58. Lola, Belete, Gebeyehu, Zerihun, Yimer, Leta (2019): Attention Deficit Hyperactivity Disorder (ADHD) among Children Aged 6 to 17 Years Old Living in Girja District, Rural Ethiopia. Behav Neurol. 2019 Apr 14;2019:1753580. doi: 10.1155/2019/1753580. eCollection 2019. ↥

  59. Aliye K, Tesfaye E, Soboka M (2023): High rate of attention deficit hyperactivity disorder among children 6 to 17 years old in Southwest Ethiopia findings from a community-based study. BMC Psychiatry. 2023 Mar 8;23(1):144. doi: 10.1186/s12888-023-04636-9. PMID: 36890504; PMCID: PMC9993367. n = 504 ↥

  60. Girma D, Abita Z, Adugna A, Alie MS, Shifera N, Abebe GF (2024): The pooled prevalence of attention-deficit/hyperactivity disorder among children and adolescents in Ethiopia: A systematic review and meta-analysis. PLoS One. 2024 Jul 18;19(7):e0307173. doi: 10.1371/journal.pone.0307173. PMID: 39024258; PMCID: PMC11257254. METASTUDY ↥

  61. Kusi-Mensah, Donnir, Wemakor, Owusu-Antwi, Omigbodun (2019): Prevalence and patterns of mental disorders among primary school age children in Ghana: correlates with academic achievement. J Child Adolesc Ment Health. 2019 Dec;31(3):214-223. doi: 10.2989/17280583.2019.1678477. n = 303 ↥

  62. [Nampijja M, Sembajjwe W, Mpairwe H, Mpango R, Kinyanda E (2022): Prevalence and correlates of neurocognitive impairment and psychiatric disorders among schoolchildren in Wakiso District, Uganda: a cross-sectional study. Wellcome Open Res. 2022 Sep 29;6:217. doi: 10.12688/wellcomeopenres.17005.2. PMID: 36873715; PMCID: PMC9975401. n = 322 ↥

  63. Daniel HMC, Braz A, Caye A, Suleman A, Fumo W, Rohde LA (2024): ADHD in Mozambique: An epidemiological investigation in a Primary School Sample. Braz J Psychiatry. 2024 Jan 19. doi: 10.47626/1516-4446-2023-3343. Epub ahead of print. PMID: 38243805. ↥

  64. Mohammadi, Zarafshan, Khaleghi, Ahmadi, Hooshyari, Mostafavi, Ahmadi, Alavi, Shakiba, Salmanian (2019): Prevalence of ADHD and Its Comorbidities in a Population-Based Sample. J Atten Disord. 2019 Dec 13:1087054719886372. doi: 10.1177/1087054719886372. n = 30.532 ↥

  65. Aljadani AH, Alshammari TS, Sadaqir RI, Alrashede NOE, Aldajani BM, Almehmadi SA, Altuhayni AS, Abouzed MA (2023): Prevalence and Risk Factors of Attention Deficit-Hyperactivity Disorder in the Saudi Population: A Systematic Review and Meta-analysis. Saudi J Med Med Sci. 2023 Apr-Jun;11(2):126-134. doi: 10.4103/sjmms.sjmms_528_22. PMID: 37252016; PMCID: PMC10211419. ↥

  66. Alghamdi, Alzaben, Alhashemi, Shaaban, Fairaq, Alsuliamani, Mahin, Ghurab, Sehlo, Koenig (2022): Prevalence and Correlates of Attention Deficit Hyperactivity Disorder among College Students in Jeddah, Saudi Arabia. Saudi J Med Med Sci. 2022 May-Aug;10(2):131-138. doi: 10.4103/sjmms.sjmms_654_21. PMID: 35602395; PMCID: PMC9121697. ↥

  67. Zafar M, Alhelali AYS, Alfuwis MSM, Alshammari WZA (2024): Relationship between attention deficit hyperactive disorders with life satisfaction among medical students in city of Hail, KSA. J Educ Health Promot. 2024 Jan 22;12:437. doi: 10.4103/jehp.jehp_334_23. PMID: 38464643; PMCID: PMC10920718. ↥

  68. Alharbi N, Alotaibi KF, Althaqel GK, Alasmari NY, Alahmari AF, Alasmari OY, Alshahrani MS, Alghamdi LA, Alrashed HA, Shugair NA (2023): Adult Attention Deficit Hyperactivity Disorder (ADHD) among residents of Saudi Arabia: a cross-sectional study. Eur Rev Med Pharmacol Sci. 2023 Nov;27(22):10935-10943. doi: 10.26355/eurrev_202311_34461. PMID: 38039023. ↥

  69. Al-Yateem N, Slewa-Younan S, Halimi A, Saeed SA, Tliti D, Mohammad M, Ridwan M, Zeidan R, Hammash MH, Ahmed FR, Dias JM, Rahman SA, Subu MA, Hijazi H, Yeganeh F, Momani A, Zandi M, Mottershead R (2023): Prevalence of Undiagnosed Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in the Young Adult Population of the United Arab Emirates: A National Cross-Sectional Study. J Epidemiol Glob Health. 2023 Dec 11. doi: 10.1007/s44197-023-00167-4. PMID: 38079098. n = 406 ↥

  70. Mahrous NN, Albaqami A, Saleem RA, Khoja B, Khan MI, Hawsawi YM (2024): The known and unknown about attention deficit hyperactivity disorder (ADHD) genetics: a special emphasis on Arab population. Front Genet. 2024 Aug 6;15:1405453. doi: 10.3389/fgene.2024.1405453. PMID: 39165752; PMCID: PMC11333229. REVIEW ↥

  71. Younis EA, Shalaby SES, Abdo SAE. Screening of attention deficit hyperactivity disorder among preschool children Gharbia Governorate, Egypt. BMC Psychiatry. 2023 Apr 25;23(1):285. doi: 10.1186/s12888-023-04785-x. PMID: 37098572; PMCID: PMC10126573. n = 1.048 ↥

  72. Shebl EM, Abu Bakr Elsaid NM, Hassan HA, Kamal D, Araby E (2023): Attention-deficit hyperactivity disorder in Egyptian medical students and how it relates to their academic performance. J Family Community Med. 2023 Oct-Dec;30(4):287-294. doi: 10.4103/jfcm.jfcm_59_23. PMID: 38044975; PMCID: PMC10688586. n =990 ↥

  73. Fischer, Krause (2019): “Wir waren alle mal schwarz”, Interview, Süddeutsche Zeitung, 23./24.11.29019, Seite 33 german ↥

  74. Cénat, Kokou-Kpolou, Blais-Rochette, Morse, Vandette, Dalexis, Darius, Noorishad, Labelle, Kogan (2022): Prevalence of ADHD among Black Youth Compared to White, Latino and Asian Youth: A Meta-Analysis. J Clin Child Adolesc Psychol. 2022 Apr 15:1-16. doi: 10.1080/15374416.2022.2051524. PMID: 35427201. METASTUDIE ↥ ↥ ↥ ↥

  75. Fleming M, Fitton CA, Steiner MFC, McLay JS, Clark D, King A, Mackay DF, Pell JP (2017): Educational and Health Outcomes of Children Treated for Attention-Deficit/Hyperactivity Disorder. JAMA Pediatr. 2017 Jul 3;171(7):e170691. doi: 10.1001/jamapediatrics.2017.0691. PMID: 28459927; PMCID: PMC6583483. n = 766.244 ↥

  76. Morgan PL, Staff J, Hillemeier MM, Farkas G, Maczuga S (2013): Racial and ethnic disparities in ADHD diagnosis from kindergarten to eighth grade. Pediatrics. 2013 Jul;132(1):85-93. doi: 10.1542/peds.2012-2390. PMID: 23796743; PMCID: PMC3691530. ↥

  77. Coker TR, Elliott MN, Toomey SL, Schwebel DC, Cuccaro P, Tortolero Emery S, Davies SL, Visser SN, Schuster MA (2016): Racial and Ethnic Disparities in ADHD Diagnosis and Treatment. Pediatrics. 2016 Sep;138(3):e20160407. doi: 10.1542/peds.2016-0407. PMID: 27553219; PMCID: PMC5684883. ↥

  78. https://thrive.kaiserpermanente.org/care-near-you/northern-california/sanfrancisco/departments/release-of-medical-information/ ↥

  79. Chung, Jiang, Paksarian, Nikolaidis, Castellanos, Merikangas, Milham (2019): Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder Among Adults and Children of Different Racial and Ethnic Groups. JAMA Netw Open. 2019 Nov 1;2(11):e1914344. doi: 10.1001/jamanetworkopen.2019.14344. n = 5,2 Mio Patienten, n = 59.371 ADHS-Betroffene ↥

  80. Pagerols M, Valero S, Dueñas L, Bosch R, Casas M (2023): Psychiatric disorders and comorbidity in a Spanish sample of prisoners at the end of their sentence: Prevalence rates and associations with criminal history. Front Psychol. 2023 Jan 12;13:1039099. doi: 10.3389/fpsyg.2022.1039099. PMID: 36710755; PMCID: PMC9878681. n = 140 ↥ ↥

  81. Young, González, Mutch, Mallet-Lambert, O’Rourke, Hickey, Asherson, Gudjonsson (2016): Diagnostic accuracy of a brief screening tool for attention deficit hyperactivity disorder in UK prison inmates. Psychol Med. 2016 May;46(7):1449-58. doi: 10.1017/S0033291716000039. PMID: 26867860. n = 390 ↥

  82. Baggio S, Efthimiou O (2024): Meta-analysis of the prevalence of attention-deficit hyperactivity disorder in prison: A comment on Fazel and Favril (2024) and reanalysis of the data. Crim Behav Ment Health. 2024 Jun 14. doi: 10.1002/cbm.2347. PMID: 38873856. METASTUDY, k = 28, n = 7.710 ↥ ↥

  83. Tully (2022): Management of ADHD in Prisoners-Evidence Gaps and Reasons for Caution. Front Psychiatry. 2022 Mar 18;13:771525. doi: 10.3389/fpsyt.2022.771525. PMID: 35370827; PMCID: PMC8973692. ↥ ↥

  84. Fazel S, Favril L (2024): Prevalence of attention-deficit hyperactivity disorder in adult prisoners: An updated meta-analysis. Crim Behav Ment Health. 2024 Jun;34(3):339-346. doi: 10.1002/cbm.2337. PMID: 38568877. METASTUDY, k = 11, n = 3.919 ↥

  85. Blackmore, Gray, Boyle, Fazel, Ranasinha, Fitzgerald, Misso, Gibson-Helm (2019): Systematic Review and Meta-Analysis: The Prevalence of Mental Illness in Child and Adolescent Refugees and Asylum Seekers. J Am Acad Child Adolesc Psychiatry. 2019 Nov 25. pii: S0890-8567(19)32175-6. doi: 10.1016/j.jaac.2019.11.011. n = 779 ↥

  86. Adamis, Flynn, Wrigley, Gavin, McNicholas (20229. ADHD in Adults: A Systematic Review and Meta-Analysis of Prevalence Studies in Outpatient Psychiatric Clinics. J Atten Disord. 2022 Apr 3:10870547221085503. doi: 10.1177/10870547221085503. PMID: 35373645. METASTUDY, k = 14, n = 9.444 ↥

  87. Syed H, Masaud TM, Nkire N, Iro C, Garland MR (2010): Estimating the prevalence of adult ADHD in the psychiatric clinic: a cross-sectional study using the adult ADHD self-report scale (ASRS). Ir J Psychol Med. 2010 Dec;27(4):195-197. doi: 10.1017/S079096670000152X. PMID: 30199931. n = 243 ↥

  88. Rao, Place (2015): Prevalence of ADHD in four general adult outpatient clinics in North East England. Prog Neurol Psychiatry 2011;15(5):7-10 ↥

  89. Nylander L, Holmqvist M, Gustafson L, Gillberg C (2009): ADHD in adult psychiatry. Minimum rates and clinical presentation in general psychiatry outpatients. Nord J Psychiatry. 2009;63(1):64-71. doi: 10.1080/08039480802416323. PMID: 18991159. n = 141 ↥

  90. Deberdt W, Thome J, Lebrec J, Kraemer S, Fregenal I, Ramos-Quiroga JA, Arif M (2015): Prevalence of ADHD in nonpsychotic adult psychiatric care (ADPSYC): A multinational cross-sectional study in Europe. BMC Psychiatry. 2015 Oct 13;15:242. doi: 10.1186/s12888-015-0624-5. PMID: 26462666; PMCID: PMC4604704. n = 1.986 ↥

  91. Miesch, Deister (2018): Die Aufmerksamkeitsdefizit- und Hyperaktivitätsstörung (ADHS) in der Erwachsenenpsychiatrie: Erfassung der ADHS-12-Monatsprävalenz, der Risikofaktoren und Komorbidität bei ADHS; Attention-deficit/hyperactivity disorder (ADHD) in adult psychiatry: Data on 12-month prevalence, risk factors and comorbidity; Fortschr Neurol Psychiatr. 2018 Feb 28. doi: 10.1055/s-0043-119987. DOI: 10.1055/s-0043-119987, n = 166 ↥

Previous page Next page